Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis.

18 However, in another research investigation regarding weight loss with the combination therapy of canagliflozin and phentermine, the reduction in body weight with canagliflozin alone versus placebo (difference, –1.3%; 95% CI, –3.1 to 0.4) did not reach statistical significance. 20 It should be noted that previous studies on the weightloss effects of the SGLT2 inhibitor in a non-diabetic population have been largely limited in the numbers of participants and the regimens.

also in 111,027 other papers

In general, SGLT2 inhibitors showed a trend in decreasing WC compared to placebo in the respective study results and the pooled results from meta-analyses; however, the difference was not statistically significant (WMD, −1.29 cm; 95% CI, −2.62 to 0.04 cm) ( Fig. 4 ).

also in 53,322 other papers